• Je něco špatně v tomto záznamu ?

Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy

P. Taborska, P. Lukac, D. Stakheev, L. Rajsiglova, K. Kalkusova, K. Strnadova, L. Lacina, B. Dvorankova, J. Novotny, M. Kolar, M. Vrana, H. Cechova, S. Ransdorfova, M. Valerianova, K. Smetana, L. Vannucci, D. Smrz

. 2023 ; 13 (1) : 19079. [pub] 20231104

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000734

Soft tissue sarcomas are aggressive mesenchymal-origin malignancies. Undifferentiated pleomorphic sarcoma (UPS) belongs to the aggressive, high-grade, and least characterized sarcoma subtype, affecting multiple tissues and metastasizing to many organs. The treatment of localized UPS includes surgery in combination with radiation therapy. Metastatic forms are treated with chemotherapy. Immunotherapy is a promising treatment modality for many cancers. However, the development of immunotherapy for UPS is limited due to its heterogeneity, antigenic landscape variation, lower infiltration with immune cells, and a limited number of established patient-derived UPS cell lines for preclinical research. In this study, we established and characterized a novel patient-derived UPS cell line, JBT19. The JBT19 cells express PD-L1 and collagen, a ligand of the immune checkpoint molecule LAIR-1. JBT19 cells can form spheroids in vitro and solid tumors in immunodeficient nude mice. We found JBT19 cells induce expansion of JBT19-reactive autologous and allogeneic NK, T, and NKT-like cells, and the reactivity of the expanded cells was associated with cytotoxic impact on JBT19 cells. The PD-1 and LAIR-1 ligand-expressing JBT19 cells show ex vivo immunogenicity and effective in vivo xenoengraftment properties that can offer a unique resource in the preclinical research developing novel immunotherapeutic interventions in the treatment of UPS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000734
003      
CZ-PrNML
005      
20240213093338.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-023-46305-7 $2 doi
035    __
$a (PubMed)37925511
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Taborska, Pavla $u Department of Immunology, Second Faculty of Medicine, Charles University, and Motol University Hospital, V Uvalu 84, 150 06 Praha 5, Prague, Czech Republic
245    10
$a Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy / $c P. Taborska, P. Lukac, D. Stakheev, L. Rajsiglova, K. Kalkusova, K. Strnadova, L. Lacina, B. Dvorankova, J. Novotny, M. Kolar, M. Vrana, H. Cechova, S. Ransdorfova, M. Valerianova, K. Smetana, L. Vannucci, D. Smrz
520    9_
$a Soft tissue sarcomas are aggressive mesenchymal-origin malignancies. Undifferentiated pleomorphic sarcoma (UPS) belongs to the aggressive, high-grade, and least characterized sarcoma subtype, affecting multiple tissues and metastasizing to many organs. The treatment of localized UPS includes surgery in combination with radiation therapy. Metastatic forms are treated with chemotherapy. Immunotherapy is a promising treatment modality for many cancers. However, the development of immunotherapy for UPS is limited due to its heterogeneity, antigenic landscape variation, lower infiltration with immune cells, and a limited number of established patient-derived UPS cell lines for preclinical research. In this study, we established and characterized a novel patient-derived UPS cell line, JBT19. The JBT19 cells express PD-L1 and collagen, a ligand of the immune checkpoint molecule LAIR-1. JBT19 cells can form spheroids in vitro and solid tumors in immunodeficient nude mice. We found JBT19 cells induce expansion of JBT19-reactive autologous and allogeneic NK, T, and NKT-like cells, and the reactivity of the expanded cells was associated with cytotoxic impact on JBT19 cells. The PD-1 and LAIR-1 ligand-expressing JBT19 cells show ex vivo immunogenicity and effective in vivo xenoengraftment properties that can offer a unique resource in the preclinical research developing novel immunotherapeutic interventions in the treatment of UPS.
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a antigeny CD274 $x metabolismus $7 D060890
650    _2
$a myši nahé $7 D008819
650    _2
$a ligandy $7 D008024
650    12
$a sarkom $x patologie $7 D012509
650    12
$a maligní fibrózní histiocytom $7 D051677
650    _2
$a imunoterapie $7 D007167
650    _2
$a buněčné linie $7 D002460
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lukac, Pavol $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Stakheev, Dmitry $u Department of Immunology, Second Faculty of Medicine, Charles University, and Motol University Hospital, V Uvalu 84, 150 06 Praha 5, Prague, Czech Republic $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Rajsiglova, Lenka $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Kalkusova, Katerina $u Department of Immunology, Second Faculty of Medicine, Charles University, and Motol University Hospital, V Uvalu 84, 150 06 Praha 5, Prague, Czech Republic
700    1_
$a Strnadova, Karolina $u Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Faculty of Medicine, BIOCEV, Charles University, Vestec, Czech Republic
700    1_
$a Lacina, Lukas $u Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Faculty of Medicine, BIOCEV, Charles University, Vestec, Czech Republic $u Department of Dermatovenerology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
700    1_
$a Dvorankova, Barbora $u Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Faculty of Medicine, BIOCEV, Charles University, Vestec, Czech Republic
700    1_
$a Novotny, Jiri $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kolar, Michal $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Vrana, Milena $u HLA Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Cechova, Hana $u HLA Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Ransdorfova, Sarka $u Department of Cytogenetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Valerianova, Marie $u Department of Cytogenetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Smetana, Karel $u Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic $u First Faculty of Medicine, BIOCEV, Charles University, Vestec, Czech Republic
700    1_
$a Vannucci, Luca $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Smrz, Daniel $u Department of Immunology, Second Faculty of Medicine, Charles University, and Motol University Hospital, V Uvalu 84, 150 06 Praha 5, Prague, Czech Republic. daniel.smrz@lfmotol.cuni.cz $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic. daniel.smrz@lfmotol.cuni.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 19079
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37925511 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093335 $b ABA008
999    __
$a ok $b bmc $g 2049389 $s 1210428
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 1 $d 19079 $e 20231104 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20240109
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace